Nurix Therapeutics (NRIX) Total Non-Current Liabilities (2019 - 2021)

Nurix Therapeutics (NRIX) has reported Total Non-Current Liabilities for 3 consecutive years, with $117.1 million the latest figure, recorded in Q3 2021.

• In Q3 2021, Total Non-Current Liabilities rose 13.23% year-over-year to $117.1 million; the TTM figure through Aug 2021 stood at $117.1 million (up 13.23% YoY), while the FY2020 annual figure was $105.2 million, up 103.02% from the prior year.
• Total Non-Current Liabilities eased to $117.1 million in Q3 2021 per NRIX's latest filing, from $119.0 million in the prior quarter.
• Across five years, Total Non-Current Liabilities topped out at $125.7 million in Q1 2021 and bottomed at $51.8 million in Q4 2019.
• Historically, Total Non-Current Liabilities has averaged $103.7 million across 3 years, with a median of $111.1 million in 2020.
• Annual changes were most pronounced in 2020 — Total Non-Current Liabilities jumped 103.02% — and 2021, when it increased 13.23%.
• Nurix Therapeutics' Total Non-Current Liabilities stood at $51.8 million in 2019, then surged by 103.02% to $105.2 million in 2020, then advanced by 11.25% to $117.1 million in 2021.
• Business Quant data shows NRIX's Total Non-Current Liabilities at $117.1 million in Q3 2021, $119.0 million in Q2 2021, and $125.7 million in Q1 2021.